Modulation of microRNAs in hypertension-induced arterial remodeling through the β1 and β3-adrenoreceptor pathways

Journal of Molecular and Cellular Cardiology

Volumn 65, Issue , 2013, Pages 127-136

  Ling, Shukuan ^a,b,c   Nanhwan, Manjyot ^a   Qian, Jinqiao ^d   Kodakandla, Monica ^a   Castillo, Alexander C ^a   Thomas, Bejoy ^a   Liu, Hongju ^b   Ye, Yumei ^a  

^a University of Texas Medical Branch School of Medicine   (United States)

^b China Astronaut Research and Training Center   (China)

^c HARBIN INSTITUTE OF TECHNOLOGY   (China)

^d KUNMING MEDICAL UNIVERSITY   (China)

Author keywords

1 receptors; 3 receptors; Arterial dysfunction; Hypertension; MicroRNA; Vascular remodeling

Indexed keywords

4 [2 [[2 (3 CHLOROPHENYL) 2 HYDROXYETHYL]AMINO]PROPYL]PHENOXYACETIC ACID; ATENOLOL; BETA 1 ADRENERGIC RECEPTOR; BETA 3 ADRENERGIC RECEPTOR; CYANOPINDOLOL; ENDOTHELIAL NITRIC OXIDE SYNTHASE; INSULIN GROWTH FACTOR 1 RECEPTOR; LUCIFERASE; MICRORNA; MICRORNA 21; MICRORNA 26B; MICRORNA 320; NEBIVOLOL; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; SOMATOMEDIN RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERY DISEASE; ARTICLE; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; GENE CONTROL; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; HEART PROTECTION; HYPERTENSION; IN VIVO STUDY; MALE; MICROARRAY ANALYSIS; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN RNA BINDING; PROTEIN TARGETING; RAT; SIGNAL TRANSDUCTION; UPREGULATION;

RATTUS;

ARTERIAL DYSFUNCTION; HYPERTENSION; MICRORNA; VASCULAR REMODELING; Β1 RECEPTORS; Β3 RECEPTORS;

ADRENERGIC BETA-ANTAGONISTS; ANIMALS; AORTA; ATENOLOL; ATRIAL REMODELING; BENZOPYRANS; CARDIOMEGALY; COLLAGEN; ETHANOLAMINES; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HYPERTENSION; LUCIFERASES; MICRORNAS; MYOCYTES, SMOOTH MUSCLE; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PTEN PHOSPHOHYDROLASE; RATS; RATS, INBRED DAHL; RECEPTOR, IGF TYPE 1; RECEPTORS, ADRENERGIC, BETA-1; RECEPTORS, ADRENERGIC, BETA-3; SIGNAL TRANSDUCTION; SODIUM CHLORIDE, DIETARY;

EID: 84887199926     PISSN: 00222828     EISSN: 10958584     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2013.10.003     Document Type: Article

References (47)

1. Divakaran V., Mann D.L. The emerging role of microRNAs in cardiac remodeling and heart failure. Circ Res 2008, 103:1072-1083.
2. Guo L., Qiu Z., Wei L., Yu X., Gao X., Jiang S., et al. The microRNA-328 regulates hypoxic pulmonary hypertension by targeting at insulin growth factor 1 receptor and L-type calcium channel-alpha1C. Hypertension 2012, 59:1006-1013.
3. Liu Y., Taylor N.E., Lu L., Usa K., Cowley A.W., Ferreri N.R., et al. Renal medullary microRNAs in Dahl salt-sensitive rats: miR-29b regulates several collagens and related genes. Hypertension 2010, 55:974-982.
4. Lorenzen J.M., Martino F., Thum T. Epigenetic modifications in cardiovascular disease. Basic Res Cardiol 2012, 107:245.
5. Sayed D., Hong C., Chen I.Y., Lypowy J., Abdellatif M. MicroRNAs play an essential role in the development of cardiac hypertrophy. Circ Res 2007, 100:416-424.
6. Meder B., Keller A., Vogel B., Haas J., Sedaghat-Hamedani F., Kayvanpour E., et al. MicroRNA signatures in total peripheral blood as novel biomarkers for acute myocardial infarction. Basic Res Cardiol 2011, 106:13-23.
7. Krutzfeldt J., Rajewsky N., Braich R., Rajeev K.G., Tuschl T., Manoharan M., et al. Silencing of microRNAs in vivo with 'antagomirs'. Nature 2005, 438:685-689.
8. Hebert P.R., Moser M., Mayer J., Glynn R.J., Hennekens C.H. Recent evidence on drug therapy of mild to moderate hypertension and decreased risk of coronary heart disease. Arch Intern Med 1993, 153:578-581.
9. Cosentino F., Bonetti S., Rehorik R., Eto M., Werner-Felmayer G., Volpe M., et al. Nitric-oxide-mediated relaxations in salt-induced hypertension: effect of chronic beta1 -selective receptor blockade. J Hypertens 2002, 20:421-428.
10. van Zwieten P.A. Nebivolol and endothelium dysfunction in salt-sensitive Dahl rats. J Hypertens 2002, 20:357.
11. Lin H., Qian J., Castillo A.C., Long B., Keyes K.T., Chen G., et al. Effect of miR-23 on oxidant-induced injury in human retinal pigment epithelial cells. Invest Ophthalmol Vis Sci 2011, 52:6308-6314.
12. Ye Y., Hu Z., Lin Y., Zhang C., Perez-Polo J.R. Downregulation of microRNA-29 by antisense inhibitors and a PPAR-gamma agonist protects against myocardial ischaemia-reperfusion injury. Cardiovasc Res 2010, 87:535-544.
13. Sarkar R., Meinberg E.G., Stanley J.C., Gordon D., Webb R.C. Nitric oxide reversibly inhibits the migration of cultured vascular smooth muscle cells. Circ Res 1996, 78:225-230.
14. Groot D., Rao J., Johnston P., Nakatsui T. Algorithm for using a long-pulsed Nd:YAG laser in the treatment of deep cutaneous vascular lesions. Dermatol Surg 2003, 29:35-42.
15. Lee S., Chanoit G., McIntosh R., Zvara D.A., Xu Z. Molecular mechanism underlying Akt activation in zinc-induced cardioprotection. Am J Physiol Heart Circ Physiol 2009, 297:H569-H575.
16. Shan Y.X., Yang T.L., Mestril R., Wang P.H. Hsp10 and Hsp60 suppress ubiquitination of insulin-like growth factor-1 receptor and augment insulin-like growth factor-1 receptor signaling in cardiac muscle: implications on decreased myocardial protection in diabetic cardiomyopathy. J Biol Chem 2003, 278:45492-45498.
17. Lee J.O., Yang H., Georgescu M.M., Di Cristofano A., Maehama T., Shi Y., et al. Crystal structure of the PTEN tumor suppressor: implications for its phosphoinositide phosphatase activity and membrane association. Cell 1999, 99:323-334.
18. Oudit G.Y., Sun H., Kerfant B.G., Crackower M.A., Penninger J.M., Backx P.H. The role of phosphoinositide-3 kinase and PTEN in cardiovascular physiology and disease. J Mol Cell Cardiol 2004, 37:449-471.
19. Maegdefessel L., Azuma J., Toh R., Merk D.R., Deng A., Chin J.T., et al. Inhibition of microRNA-29b reduces murine abdominal aortic aneurysm development. J Clin Invest 2012, 122:497-506.
20. Creemers E.E., Tijsen A.J., Pinto Y.M. Circulating microRNAs: novel biomarkers and extracellular communicators in cardiovascular disease?. Circ Res 2012, 110:483-495.
21. van Rooij E., Olson E.N. MicroRNAs: powerful new regulators of heart disease and provocative therapeutic targets. J Clin Invest 2007/09/06, 2369-2376. ed2007.
22. Ikeda S., Kong S.W., Lu J., Bisping E., Zhang H., Allen P.D., et al. Altered microRNA expression in human heart disease. Physiol Genomics 2007, 31:367-373.
23. Wang X.H., Qian R.Z., Zhang W., Chen S.F., Jin H.M., Hu R.M. MicroRNA-320 expression in myocardial microvascular endothelial cells and its relationship with insulin-like growth factor-1 in type 2 diabetic rats. Clin Exp Pharmacol Physiol 2009, 36:181-188.
24. Ren X.P., Wu J., Wang X., Sartor M.A., Qian J., Jones K., et al. MicroRNA-320 is involved in the regulation of cardiac ischemia/reperfusion injury by targeting heat-shock protein 20. Circulation 2009, 119:2357-2366.
25. Palumbo T., Faucz F.R., Azevedo M., Xekouki P., Iliopoulos D., Stratakis C.A. Functional screen analysis reveals miR-26b and miR-128 as central regulators of pituitary somatomammotrophic tumor growth through activation of the PTEN-AKT pathway. Oncogene 2013, 32(13):1651-1659. [Epub 2012 May 21]. 10.1038/onc.2012.190.
26. Han M., Yang Z., Sayed D., He M., Gao S., Lin L., et al. GATA4 expression is primarily regulated via a miR-26b-dependent post-transcriptional mechanism during cardiac hypertrophy. Cardiovasc Res 2012, 93:645-654.
27. Albinsson S., Skoura A., Yu J., DiLorenzo A., Fernandez-Hernando C., Offermanns S., et al. Smooth muscle miRNAs are critical for post-natal regulation of blood pressure and vascular function. PLoS One 2011, 6:e18869.
28. Pullamsetti S.S., Doebele C., Fischer A., Savai R., Kojonazarov B., Dahal B.K., et al. Inhibition of microRNA-17 improves lung and heart function in experimental pulmonary hypertension. Am J Respir Crit Care Med 2012, 185:409-419.
29. Zheng L., Xu C.C., Chen W.D., Shen W.L., Ruan C.C., Zhu L.M., et al. MicroRNA-155 regulates angiotensin II type 1 receptor expression and phenotypic differentiation in vascular adventitial fibroblasts. Biochem Biophys Res Commun 2010, 400:483-488.
30. Roy S., Khanna S., Hussain S.R., Biswas S., Azad A., Rink C., et al. MicroRNA expression in response to murine myocardial infarction: miR-21 regulates fibroblast metalloprotease-2 via phosphatase and tensin homologue. Cardiovasc Res 2009, 82:21-29.
31. Ji R., Cheng Y., Yue J., Yang J., Liu X., Chen H., et al. MicroRNA expression signature and antisense-mediated depletion reveal an essential role of microRNA in vascular neointimal lesion formation. Circ Res 2007, 100:1579-1588.
32. Parikh V.N., Jin R.C., Rabello S., Gulbahce N., White K., Hale A., et al. MicroRNA-21 integrates pathogenic signaling to control pulmonary hypertension: results of a network bioinformatics approach. Circulation 2012, 125:1520-1532.
33. Yang S., Banerjee S., Freitas A., Cui H., Xie N., Abraham E., et al. miR-21 regulates chronic hypoxia-induced pulmonary vascular remodeling. Am J Physiol Lung Cell Mol Physiol 2012, 302:L521-L529.
34. Naito Y., Hirotani S., Sawada H., Akahori H., Tsujino T., Masuyama T. Dietary iron restriction prevents hypertensive cardiovascular remodeling in Dahl salt-sensitive rats. Hypertension 2011, 57:497-504.
35. Dey N., Ghosh-Choudhury N., Kasinath B.S., Choudhury G.G. TGFbeta-stimulated microRNA-21 utilizes PTEN to orchestrate AKT/mTORC1 signaling for mesangial cell hypertrophy and matrix expansion. PLoS One 2012, 7:e42316.
36. Kumarswamy R., Volkmann I., Jazbutyte V., Dangwal S., Park D.H., Thum T. Transforming growth factor-beta-induced endothelial-to-mesenchymal transition is partly mediated by microRNA-21. Arterioscler Thromb Vasc Biol 2012, 32:361-369.
37. Liang H., Zhang C., Ban T., Liu Y., Mei L., Piao X., et al. A novel reciprocal loop between microRNA-21 and TGFbetaRIII is involved in cardiac fibrosis. Int J Biochem Cell Biol 2012, 44:2152-2160.
38. Patel V., Noureddine L. MicroRNAs and fibrosis. Curr Opin Nephrol Hypertens 2012, 21:410-416.
39. Patrick D.M., Montgomery R.L., Qi X., Obad S., Kauppinen S., Hill J.A., et al. Stress-dependent cardiac remodeling occurs in the absence of microRNA-21 in mice. J Clin Invest 2010, 120:3912-3916.
40. Bailey-Downs L.C., Mitschelen M., Sosnowska D., Toth P., Pinto J.T., Ballabh P., et al. Liver-specific knockdown of IGF-1 decreases vascular oxidative stress resistance by impairing the Nrf2-dependent antioxidant response: a novel model of vascular aging. J Gerontol A Biol Sci Med Sci 2012, 67:313-329.
41. Colao A., Di Somma C., Cascella T., Pivonello R., Vitale G., Grasso L.F., et al. Relationships between serum IGF1 levels, blood pressure, and glucose tolerance: an observational, exploratory study in 404 subjects. Eur J Endocrinol 2008, 159:389-397.
42. Zhang B., Turdi S., Li Q., Lopez F.L., Eason A.R., Anversa P., et al. Cardiac overexpression of insulin-like growth factor 1 attenuates chronic alcohol intake-induced myocardial contractile dysfunction but not hypertrophy: roles of Akt, mTOR, GSK3beta, and PTEN. Free Radic Biol Med 2010, 49:1238-1253.
43. Sesti G., Sciacqua A., Scozzafava A., Vatrano M., Angotti E., Ruberto C., et al. Effects of growth hormone and insulin-like growth factor-1 on cardiac hypertrophy of hypertensive patients. J Hypertens 2007, 25:471-477.
44. Feng M.G., Prieto M.C., Navar L.G. Nebivolol-induced vasodilation of renal afferent arterioles involves beta3-adrenergic receptor and nitric oxide synthase activation. Am J Physiol Renal Physiol 2012, 303:F775-F782.
45. Crackower M.A., Oudit G.Y., Kozieradzki I., Sarao R., Sun H., Sasaki T., et al. Regulation of myocardial contractility and cell size by distinct PI3K-PTEN signaling pathways. Cell 2002, 110:737-749.
46. Oudit G.Y., Kassiri Z., Zhou J., Liu Q.C., Liu P.P., Backx P.H., et al. Loss of PTEN attenuates the development of pathological hypertrophy and heart failure in response to biomechanical stress. Cardiovasc Res 2008, 78:505-514.
47. Xiao H., Lv F., Xu W., Zhang L., Jing P., Cao X. Deprenyl prevents MPP(+)-induced oxidative damage in PC12 cells by the upregulation of Nrf2-mediated NQO1 expression through the activation of PI3K/Akt and Erk. Toxicology 2011, 290:286-294.